US-based precision medicine firm InterVenn Biosciences has announced it has its US$34 million Series B round of funding. The round was led by Anzu Partners with full participation of Genoa Ventures, Amplify Partners, and True Ventures; Malaysia based Xeraya Capital and the Ojjeh Family.
InterVenn will use the funds to commercialize the company’s High-Throughput-Glycoproteomic powered diagnostic for ovarian cancer; to service increasing partnership platform demand; and to accelerate development efforts for the immuno-oncology treatment response and colorectal cancer indications.
According to Crunchbase, InterVenn has raised a total of US$43 million to date, which also included its US$9.4 million Series A in 2018.
InterVenn utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.